Clinical Trials Actively Recruiting in Canada

Breakdown for each trial:
• Name of trial
• Short summary
• Countries recruiting
• Link to trial page on
• Trial Status

Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia

Oseltamivir is an attractive drug for ITP since it specifically targets a pathophysiologic mechanism that appears to be important for the development of ITP and has a benign side effect profile compared to standard ITP therapy. This pilot, proof-of-concept, randomized controlled clinical trial has the potential to dramatically change the treatment of ITP.


Status: Unknown

A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

Principia Biopharma is conducting a study of their oral drug PRN1008 in patients with ITP who are refractory or relapsed with no available and approved therapeutic options and have a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15 days before treatment begins. Preclinical findings show that PRN1008 decreases the activity of B cells and other inflammatory-causing immune cells, and in a mouse model of ITP show that PRN1008 can reduce platelet loss.

USA, Australia, Bulgaria, Canada, Czech Republic, Netherlands, Norway, and United Kingdom


BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo